Biolinq, a healthcare technology company pioneering precision multi-analyte biosensors to improve metabolic health, announced a $100 million Series C funding round led by Alpha Wave Ventures. Existing investors RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical, and Features Capital participated.
This funding round will support Biolinq through the US regulatory approval process as the company prepares to bring the first autonomous intradermal glucose sensor to market. And Biolinq’s initial product is a wearable biosensor powered by an array of tiny electrochemical sensors that continuously measure glucose levels beneath the skin’s surface.
Biolinq’s glucose sensor patch placed on the upper forearm has a color-changing indicator light, providing users with real-time feedback to stay informed about glucose excursions. And the company’s first-generation glucose sensor is designed for ease of use and reliability leveraging a biosensing platform that enables future multi-analyte sensing capabilities.
Biolinq’s intradermal glucose sensor is an investigational device and it has not yet been cleared or approved by the FDA or any other regulatory authority.
KEY QUOTES:
“This financing will bolster Biolinq’s commercial readiness efforts while we pursue regulatory approval for the first intradermal glucose sensor that incorporates activity and sleep information into a single wearable device. Our team has spent the last decade developing a biosensor platform designed to inspire healthier living by providing context around a person’s metabolic health.”
Rich Yang, CEO
“Biolinq has assembled world-class experts in biosensor technology, consumer electronics, and semiconductor manufacturing to redefine the biowearables category. With a highly differentiated product, Biolinq is well-positioned to expand the biosensor market.”
Rick Gerson, Chairman of Alpha Wave Global
“Biolinq is unlocking a new era of biosensing technology, making glucose information simpler and more accessible. This technology has the potential to help restore metabolic health for millions of people living with Type 2 diabetes not using insulin.”
Dan Bradbury, Chairman of Biolinq
